CymaBay Therapeutics Inc. (CBAY) is getting acquired by Gilead Sciences Inc. (GILD) for $32.50 per share in cash or a total equity value of $4.3 billion.
The company's lead drug candidate is Seladelpar, being developed for the management of primary biliary cholangitis. Seladelpar is under priority review by the FDA, with a decision due on August 14, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com